Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers

• Published in: British journal of clinical pharmacology Vol. 88; no. 7; pp. 3307 - 3320
• Main Authors: Bian, Yicong, Meng, Jian, Ma, Sheng, Li, Guangze, Wang, Yuya, Li, Shaorong, Liu, Linsheng, Huang, Chenrong, Zhang, Hua, Zhong, Dafang, Miao, Liyan
• Format: Journal Article
• Language: English
• Published: England 01.07.2022
• Subjects: fuzuloparib; mass balance; metabolite profiles; PARP; pharmacokinetics; pharmacokinetics; PARP; fuzuloparib; mass balance; metabolite profiles

Aim This trial (NCT04013048) investigated the metabolite profiles, mass balance and pharmacokinetics of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers. Methods A single dose of 150 mg [14C]fuzuloparib was administered to five subjects with advanc...